^
Association details:
Biomarker:IL6-L
Cancer:Renal Cell Carcinoma
Drug:pazopanib (Multi-tyrosine kinase inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)

Published date:
05/27/2020
Excerpt:
Low baseline levels of IL-6, IL-8, HGF, and osteopontin were found to be significantly associated with objective response. In addition, patients with low baseline levels of HGF showed longer progression-free survival and overall survival, whereas patients with low baseline levels of IL-8 showed longer overall survival. Changes in levels of selected CAFs were associated with response/resistance to pazopanib in mRCC patients.
DOI:
10.1097/COC.0000000000000719
Trial ID: